Navigation Links
Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer

and safety data on 48 patients are available. The 65 patients considered evaluable for response had completed at least their 2nd cycle of treatment and had a tumor assessment, which could be compared to their baseline. This study is ongoing, and final results may change from the initial analysis.

"My colleagues and I are very excited by the results of this study so far, " said Linda T. Vahdat, MD, Associate Professor of Clinical Medicine and Medical Director, Breast Cancer Program at Cornell University New York Presbyterian Hospital. "We look forward to additional studies with this novel compound."

Pre-clinical studies demonstrate that E7389 suppresses the growth of cellular microtubules, which are essential for cell division. By doing so, E7389 appears to stop the production of new cancer cells and ultimately results in the programmed death of the existing cancer cells, a process known as apoptosis.


'"/>

Source:JFK Communcations


Page: 1 2

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
4. GlycoFi announces the first production of antibodies with human glycosylation in yeast
5. NHGRI announces new sequencing targets
6. CHAVI announces international search for genes affecting HIV response
7. NHGRI announces latest sequencing targets
8. MUHC announces a transplant first in Quebec
9. St. Jude announces breakthrough in eye cancer treatment
10. NIH announces phase III clinical trial of creatine for Parkinsons disease
11. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
Post Your Comments:
(Date:7/11/2014)... This news release is available in German . ... imaging is a method that uses the refraction of ... absorption. The images produced with this method are often ... The scientists in the team of Prof. Franz Pfeiffer ... X-ray imaging and therapy including X-ray phase-contrast imaging. ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... NY) Many egg donation agencies and private couples routinely ... study finds. From a sample of over 300 ... offered payment in excess of $10,000, a violation of ... (ASRM). Compensation strongly correlated with average ...
... PITTSBURGH, March 24 An experimental vaccine against an ... delay the onset of inflammatory bowel disease (IBD) and in ... the University of Pittsburgh School of Medicine. Their findings are ... journal of the American Association for Cancer Research. People ...
... weather in the Canadian Arctic could create problems for nesting ... have spent over 7,000 days observing birds in the North. ... cold, dry summers that mark the high Arctic. However, warmer ... fog, rain, freezing rain, wet snow and stronger winds. ...
Cached Biology News:Fertility industry offers big money to recruit 'desirable' egg donors at top universities 2Vaccine could delay bowel inflammation and colon cancer, says Pitt research 2Warmer summers could create challenges for nesting Arctic seabirds 2Warmer summers could create challenges for nesting Arctic seabirds 3
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
(Date:7/10/2014)... have observed the fractional quantum Hall effect in bilayer ... can be tuned by an electric field. , ... electrons confined to thin sheets are exposed to large ... where thousands of individual electrons behave as a single ... is well established, many details of this collective behavior ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
... US: CXM) today announced the completion of a $3.5 million ... to purchase shares of common stock. Empire Asset Management Company ... transaction. The material terms of the credit facility are ... Form 8-K to be filed with the Securities and Exchange ...
... KENILWORTH, N.J., March 5 Schering-Plough Corporation (NYSE: ... of a presentation by David Nicholson, Ph.D., senior vice ... Institute, at the Barclays Capital Global Healthcare Conference in ... EDT. Nicholson is expected to talk about the ...
... Experts from PAREXEL International Corporation (Nasdaq: ... will address important industry issues at the Drug ... from March 23 - 25, 2009 in Berlin, ... present on topics ranging from global biosimilar development ...
Cached Biology Technology:Cardium Completes $3.5 Million Credit Facility 2Cardium Completes $3.5 Million Credit Facility 3Cardium Completes $3.5 Million Credit Facility 4PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 2PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 3PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 4PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 5
Mouse monoclonal antibody to QARS - glutaminyl-tRNA synthetase...
... DNA polymerase obtained by high level expression ... E. coli, Concentration: 5U/ul, Applications: Standard PCR ... the world leader in serving science. Thermo ... world healthier, cleaner and safer by providing ...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... MasterAmp™ Taq DNA Polymerase is a ... aquaticus. Having optimal activity at temperatures ... thermostable enzyme used for PCR and ... purpose. The enzyme has an intrinsic ...
Biology Products: